Contrasting Endonovo Therapeutics (OTCMKTS:ENDVD) and NexImmune (OTCMKTS:NEXI)

Valuation & Earnings

This table compares NexImmune and Endonovo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexImmune	N/A	N/A	-$32.34 million	($18.29)	N/A
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A

Endonovo Therapeutics has higher revenue and earnings than NexImmune.

Risk and Volatility

NexImmune has a beta of -2282.12, meaning that its stock price is 228,312% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Institutional and Insider Ownership

9.9% of NexImmune shares are held by institutional investors. 14.9% of NexImmune shares are held by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares NexImmune and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexImmune	N/A	N/A	N/A
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.